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Methods: This retrospective study included 106 consecutive patients with RA in
Fuwai cardiovascular disease hospital between January 2010 and January 2012, all of
them had been conﬁrmed as coronary disease by coronary angiography. At this
sampling 46 RA patients were developed MI. The control group includes 60 subjects
who were free of MI. The characteristics of both groups were compared including
demographics, traditional cardiovascular risks and laboratory ﬁndings. Cases of MI
and controls were compared by disease activity variables and risk factors using the
student’s t test (for continuous variables) or the c2test (for dichotomous variables).
Variables that had a P value of <0.2 in the single factor logistic regression were
entered into a multivariate model.
Results: There were no signiﬁcant differences about demographics, traditional car-
diovascular between MI group and control group, such as age, gender, Body Mass
Index (BMI), the percentage of hypertension (HT), diabetes mellitus (DM), hyper-
lipidaemia (HLP) and Smoking. MI group showed increased Erythrocyte Sedimen-
tation Rate (ESR) (P¼0.014),C-reactive protein (CRP) (P¼0.000) and creatinine
(P¼0.024) levels than control group. The result of univariate logistic’s regression
demonstrated that ESR (P¼0.009), CRP (P¼0.022), CR (P¼0.030), lipoproteins (LP-
a) (P¼0.097) and high-sensitivity C-reactive protein (Hs-CRP) (P¼0.009) are asso-
ciated with increased risk of MI in RA. The result of analysis of multivariate logistic’s
regression showed that ESR [OR 95% CI 1.024 (1.007-1.043), P¼0.007] was an
independent risk factor of MI in RA patients.
Conclusions: Patients with RA who developed MI had similar traditional cardio-
vascular risk factors compared to RA patients without MI, but had signiﬁcant dif-
ferences in inﬂammatory indexes. Inﬂammation may accelerate atherogenesis and
have an excess risk of MI in RA patient with cardiovascular disease.
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Nebivolol Protects against Myocardial Infarction Injury via Stimulation of beta
3-Adrenergic Receptors and Nitric Oxide Signaling
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Objectives: Nebivolol, third-generation b-blocker, may activate b3-adrenergic re-
ceptor (AR), which has been emerged as a novel and potential therapeutic targets for
cardiovascular diseases. However, it is not known whether nebivolol administration
plays a cardioprotective effect against myocardial infarction (MI) injury. Therefore,
the present study was designed to clarify the effects of nebivolol on MI injury and to
elucidate the underlying mechanism.
Methods: MI model was constructed by left anterior descending (LAD) artery liga-
tion. Nebivolol, SR59230A (SR), Nitro-L-arginine methylester (L-NAME) or vehicle
was administered one day after MI operation. Cardiac function was monitored by
echocardiography. Moreover, the ﬁbrosis and the apoptosis of myocardium were
assessed by Masson’s trichrome stain and TUNEL assay respectively.
Results: Nebivolol administration reduced scar area by 68% compared with MI group
(P<0.05). Meanwhile, nebivolol also decreased the myocardial apoptosis and
improved the heart function after MI (P<0.05 vs. MI). These effects were associated
with increased b3-AR expression. Furthermore, nebivolol treatment signiﬁcantly
increased the phosphorylation of endothelial NOS (eNOS) and the expression of
neuronal NOS (nNOS). Conversely, the cardiac protective effects of nebivolol were
abolished by SR and L-NAME.
Conclusions: These results indicate that nebivolol protects against MI injury.
Furthermore, the cardioprotective effects of nebivolol may be mediated by b3-AR-
eNOS/nNOS pathway.
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Objectives: The association of single nucleotide polymorphisms (SNPs) in the
glucokinase (hexokinase 4) regulator (GCKR) gene and serum lipid levels is incon-
sistent. The goal of this study was to test the association between polymorphisms in
the GCKR gene and serum lipid levels, and the risk of coronary artery disease (CAD)
and ischemic stroke (IS) in the Guangxi Han population and to identify the potential
mechanism.
Methods: Genotyping of the GCKR rs1260326 and rs8179206 SNPs in 1736 unre-
lated subjects (CAD, 584; IS, 555; and healthy controls; 597) was performed by
Snapshot technology platform. Coronary angiography was performed in patients with
CAD. CAD was deﬁned as signiﬁcant coronary stenosis (> 50%) in at least either one
of the three main coronary arteries or their major branches (branch diameter>2 mm).
The patients with is received strict neurological examination and brain magnetic
resonance imaging scan. It was diagnosed according to the International Classiﬁcation
of Diseases (9th Revision).
Results: The genotypic and allelic frequencies of rs1260326 and rs8179206 SNPs
were not signiﬁcantly different between controls and CAD or IS patients, or between
CAD and IS patients (P>0.05 for all). The subjects with TT genotype of rs1260326
SNP had higher serum low-density lipoprotein cholesterol (LDL-C) levels in controlsJACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/Cand higher triglyceride (TG) levels in CAD patients than the subjects with CC and CT
genotypes (P<0.05) after adjustment of age, sex, body mass index, blood pressure,
alcohol consumption, and cigarette smoking. But this association was not found in the
IS patients.
Conclusions: The present study shows that the TT genotype of GCKR rs1260326
SNP is associated with high LDL-C levels in controls and high TG levels in the CAD
patients.
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Objectives: To assess the relationship between brachial-ankle pulse wave velocity
and left ventricular diastolic function of hospitalized patients in department of
cardiology.
Methods: Six hundred ﬁfty-two patients in department of cardiology in Peking
University First Hospital were enrolled in the study. They were hospitalized
because of cardiovascular diseases during Nov 2012 to Oct 2013. The clinical
information and echocardiography were collected. The brachial-ankle pulse wave
velocity was measured noninvasively. The patients were divided into four groups
according to left ventricular diastolic function: group of normal diastolic
function deﬁned as E/A0.8, E/ E’8; group of mild diastolic dysfunction deﬁned
as E/A<0.8, E/E’8; group of moderate diastolic dysfunction deﬁned as 0.8E/
A1.5, 8<E/E’<13; group of severe diastolic dysfunction deﬁned as E/A2.0, E/
E’ 13. baPWV were compared between four groups. The relationship between left
ventricular diastolic function and baPWV was analyzed using spearman method.
Logistic regression model was used to correction the factors inﬂuencing LV dia-
stolic function.
Results: (1) The baPWV were 1403.09256.61 cm/s, 1631.03357.67 cm/s,
1641.02605.50 cm/s and 1718.85350.53 cm/s in normal diastolic function group,
mild diastolic dysfunction group, moderate diastolic dysfunction group and severe
diastolic dysfunction group separately. The baPWV rise with left ventricular diastolic
function decreased in four groups and there was statistically signiﬁcant (P<0.001). (2)
The baPWV was signiﬁcantly negatively correlated with E/A ratio (r¼-0.257,
P<0.001), and was signiﬁcantly positively correlated with E/E’ ratio (r¼0.249,
P<0.001). (2) Multiple logistic regression analysis showed: baPWV1400 cm/s is a
danger factor to left ventricular diastolic dysfunction, the RR values were 1.93 (95%
CI 1.09-3.44, P¼0.03).
Conclusions: The baPWV is correlated with left ventricular diastolic dysfunction, and
it can be a screening method for high risk group with left ventricular diastolic
dysfunction.
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Objectives: To evaluate the predictive value of both CYP2C19 genotype and
platelet function phenotype grouping methods in clinical outcomes and bleeding
events of patients receiving clopidogrel underwent percutaneous coronary inter-
vention (PCI).
Methods: Coronary heart disease (CHD) patients administered in Fuwai hospital
underwent elective PCI and received coronary stent implantation were prospectively
enrolled during October 2012 to May 2013, who were treated with a 300-mg bolus
of clopidogrel before PCI and a 75-mg maintenance dose once daily for 1 year
thereafter, in combination with a 100-mg maintenance dose once daily of chronic
aspirin therapy. Patients were assigned into groups by genotype of CYP2C19
(extensive metabolizers, intermediate metabolizers, and poor metabolizers) and
phenotype of platelet function (clopidogrel responders, semi-responders, and non-
responders). The rates of major adverse cardiovascular events, cardiovascular
symptom events, and bleeding events were recorded during a follow-up period until
6 months after the last patient ﬁrst visit and compared among the groups deﬁned
previously.
Results: 380 patients received coronary stent implantation were enrolled in this
study, including 157 (41.3%) clopidogrel extensive metabolizers, 176 (46.3%) in-
termediate metabolizers, and 47 (12.4%) poor metabolizers according to the genotype
grouping; 98 (25.8%) were responders to clopidogrel, 149 (39.2%) were semi-re-
sponders, and 133 (35.0%) were non-responders according to the phenotype
grouping. The highest cardiovascular symptom events rate was observed in the poor
metabolizers (34.0%) as compared to the intermediate metabolizers (19.1%,
HR¼2.126, 95% CI 1.131-3.997, P¼0.019) and the extensive metabolizers (15.4%,
HR¼2.772, 95% CI 1.359-5.655, P¼0.005) when grouping by the CYP2C19
genotype, without a statistical difference of the major adverse cardiovascular events
rate or bleeding events rate. The highest bleeding events rate was observed in the
clopidogrel responders (32.7%) as compared to the semi-responders (19.0%,ardiovascular Disease Clinical Research C119
